Changes to Existing Billing Codes for Spravato® (esketamine) Nasal Spray

Effective for billing dates on or after April 1, 2022, CarePartners of Connecticut will require prior authorization for the combination drug and service G codes associated with Spravato (esketamine): G2082 and G2083. Spravato nasal spray currently requires prior authorization. For more information, refer to the Medical Drugs Requiring Prior Authorization policy on or after April 1, 2022.

Providers requesting the use of Spravato (esketamine) nasal spray are encouraged to use the following billing codes when requesting prior authorization for the provision of the drug and professional services associated with Spravato (esketamine) therapy:

• G2082 is associated with office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation.
• G2083 is associated with office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation.